Method of administering split doses of a vascular targeting agent
OwnerDavid Chaplin, Sally Hillinventors
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the use of vascular targeting agents or pharmaceutically acceptable salts thereof for administration in divided doses to a warm-blooded animal, such as a human. Also disclosed is a medicament comprising two or more fraction of doses of a vascular targeting agent, or a pharmaceutically acceptable salt thereof, which together add up to a total daily dose, or administration in divided doses for use in a method of treating a human or warm-blooded animal. A kit comprising two or more fractions of doses of a vascular targeting agent or a pharmaceutically acceptable salt thereof, which together add up to a total daily dose, for administration in divided doses is also disclosed.
Claims17
A method for producing an anti-tumor effect in a warm-blooded animal, comprising administering a total daily dose of a combretastatin or an analog thereof in two or more equal or unequal divided doses to the animal, wherein the anti-tumor effect produced using divided doses of the combrestatin or analog thereof is greater than the anti-tumor effect produced by administering the same total daily dose as a single dose.
A medicament comprising two or more equal or unequal fractions of doses of a combretastatin or analog thereof, which together add up to a total daily dose for administration in divided doses for use in a method of treating a human or warm-blooded animal by therapy, wherein the anti-tumor effect produced using divided doses of the combrestatin or analog thereof is greater than the anti-tumor effect produced by administering the same total daily dose as a single dose.
A kit comprising two or more equal or unequal fractions of doses of a combretastatin or analog thereof, which together add up to a total daily dose, for administration in divided doses, wherein the anti-tumor effect produced using divided doses of the combrestatin or analog thereof is greater than the anti-tumor effect produced by administering the same total daily dose as a single dose.
Dependencies are inferred from the claim text.